Catalyst Event
AbbVie Inc (ABBV) · Other
From KEDI U.S. Medical AI Index (KUSMAI)
4/28/2026, 12:00:00 AM
AbbVie submitted an sNDA to the FDA for upadacitinib for the treatment of alopecia areata on 2026-04-28; this potential new indication is estimated to have a ~5% positive price impact expected.
Korean Translation
애브비는 2026년 4월 28일 원형 탈모증 치료를 위한 유파다시티닙의 추가 신약 허가 신청(sNDA)을 제출함. 신규 적응증 확대로 인해 약 5%의 주가 상승이 예상됨.
Related Recent Events
Alphabet Inc (GOOGL) · Other
Ex-dividend date (2026-06-08) for a quarterly cash dividend of $0.22 per share, representing a 5% increase from the prior dividend. The dividend was declared on April 27, 2026 and is payable on June 15, 2026. A 1-2% price impact is estimated as dividend increases are generally viewed positively by the market, scheduled.
6/8/2026, 12:00:00 AM
Tempus AI Inc (TEM) · Other
Tempus to host its inaugural Investor Day on May 29, 2026, starting at 8:00 a.m. CT, scheduled.
5/29/2026, 12:00:00 AM
NVIDIA Corporation (NVDA) · Earnings Release
NVIDIA is scheduled to announce its financial results for the first quarter of fiscal year 2027, which ended on April 26, 2026. A conference call will be held on the same day. Market impact is estimated as Neutral until the actual financial data is released, scheduled.
5/20/2026, 12:00:00 AM
BioNTech SE (BNTX) · Other
The Annual General Meeting 2026 is scheduled to be held as a virtual event on May 15, 2026, scheduled. Medium impact estimated as AGMs provide critical updates on corporate governance and long-term strategy.
5/15/2026, 12:00:00 AM
Hims & Hers Health Inc (HIMS) · Earnings Release
Q1 2026 earnings results are scheduled to be released after market close on May 11, 2026. High impact expected due to historical earnings volatility; scheduled.
5/11/2026, 12:00:00 AM
Caris Life Sciences Inc (CAI) · Earnings Release
Caris Life Sciences to report first quarter 2026 financial results on May 7, 2026, scheduled.
5/7/2026, 12:00:00 AM